StreetInsider.com Blog

Some tips, comments and laughs on the stock market from the team at StreetInsider.com

Thursday, December 28, 2006

Stocks to Watch Tomorrow 12/29

Another completely dead day in the market.

We just heard that Bush will make January 2nd a federal holiday to honor President Ford. We haven't heard any word on whether the market will be opened or closed on Tuesday. The talking heads on TV said they may do a half a day.

The IPO we've been writing about recently, Fuwei Films Co., Ltd. (Nasdaq: FFHL), continues to find fans. The stock jumped nearly 35% today to $17.50. Not bad considering it was brought the the market at $8.28.

Apple Computer (Nasdaq: AAPL) gave the dip buyers another chance today after the FT rehashed the options scandal stuff (slow news day). Yeah, if Jobs is forced to leave the company the stock could drop $10-$15, but the chances of that happening are about 5%.

Microcap Point.360 (Nasdaq: PTSX) jumped 49% today and no it wasn't manipulated higher. The stock actually had legitimate news. Larger rival DG FastChannel (Nasdaq: DGIT) bought up 11.4% of the company from a hedge fund, paying up $3.25 per share in a negotiated deal dated 12/22 when the stock was at $2.40 in the open market that day. In a disclosure, DG FastChannel noted they entered a nondisclosure agreement with PTSX in August. This looks like a possible hostile takeover situation. One could speculate that DGIT and PTSX held talks but they couldn't come up with an agreement and now DGIT is trying to go around them. This may be hard. Chairman and CEO Haig Bagerdjian owns 27% of the company and Julia Stefanko, the ex-wife of former CEO Luke Stefanko, owns 17%.

Say it at so! Northfield Laboratories Inc. (Nasdaq: NFLD) finally had a up day after its blow-up last week. Has is hit a bottom? What about Sally Beauty (NYSE: SBH)? - up 2.6% today after a steady decline since negative news on the L'Oreal rights.

Encysive Pharmaceuticals Inc. (Nasdaq: ENCY) announced mid-day that the FDA finally said they will review the New Drug Application (NDA) for THELIN. Sounds like good new right? Wrong - the FDA gives the review a Class 2 resubmission status instead of the hoped for Class 1 resubmission and sets a PDUFA date of June 15. The stock drops 23.6% on the news. OUCH.

Labels: , , , , , , , , , , , , ,

0 Comments:

Post a Comment

<< Home